Semaglutide is a GLP-1 receptor agonist that mimics a natural hormone, helping to reduce appetite, slow digestion, and improve blood sugar control
Retatrutide is not ready for the public to use yet
Additionally, there is mounting concern among doctors who view the non-traditional" (e.g., D2C companies, telehealth platforms) weight loss drug market as problematic, according to a December 2024 Sermo survey
Everyones experience is a little different, but learning about the different factors involved can help you find the time that works best for you
For dual receptor agonists, trials provide measurable data on blood sugar control, weight loss, metabolic improvements, and potential side effects, guiding dosage and patient selection
We stock Semaglutide GLP1-S, Tirzepatide GLP2-T, BPC-157, and TB-500